---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-309175"
form_type: "8-K"
ticker: "CDXS"
cik: "0001200375"
company_name: "CODEXIS, INC."
filed_at: "2022-12-20T23:59:59+00:00"
generated_at: "2026-06-21T01:29:16.798727+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Codexis appoints H. Stewart Parker to Board of Directors

## Summary
- H. Stewart Parker appointed as Class II director, term expiring at 2024 annual meeting.
- Appointed to Audit Committee and Strategic Committee; Board determined independent.
- Parker will receive annual cash retainer of $50,000, plus $20,000 Audit and $10,000 Strategic committee retainers.
- Granted 37,878 restricted stock units vesting over three years; future annual grants of $100,000 in RSUs.
- Parker brings biopharma leadership experience; currently on boards of IMPEL Pharmaceuticals and Sangamo Therapeutics.

## SEC filing metadata
- accession: 0001193125-22-309175
- form_type: 8-K
- ticker: CDXS
- cik: 0001200375
- company_name: CODEXIS, INC.
- filed_at: 2022-12-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1200375/000119312522309175/0001193125-22-309175-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1200375/000119312522309175/d423687d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-309175
- JSON: https://secwatch.observer/filing/0001193125-22-309175.json
- Plain text: https://secwatch.observer/filing/0001193125-22-309175.txt

## Key facts
- Executive change
  H. Stewart Parker was appointed as Director at CODEXIS, INC..
  - Action: appointed
  - Role: Director
  source text: On December 16, 2022, the Board of Directors (the “Board”) of Codexis, Inc. (the “Company”) appointed H. Stewart Parker as a member of the Board as a Class II director with an initial term expiring at the Company’s 2024 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1200375/000119312522309175/0001193125-22-309175-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.